Pembrolizumab Alone or With Chemotherapy for 70+ Year-Old Lung Cancer Patients: A Retrospective Study.
暂无分享,去创建一个
P. Christopoulos | F. Bozorgmehr | S. Liersch | F. Eichhorn | M. Blasi | J. Kuon | R. Shah | F. Herth | M. Thomas | C. Heussel | A. Stenzinger
[1] N. Chaput,et al. The use of immunotherapy in older patients with advanced non-small cell lung cancer. , 2022, Cancer Treatment Reviews.
[2] R. Simes,et al. Generalizability of immune checkpoint inhibitor trials to real-world patients with advanced non-small cell lung cancer. , 2022, Lung cancer.
[3] M. Kriegsmann,et al. Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer , 2021, Frontiers in Oncology.
[4] S. Mohile,et al. Understanding Treatment Tolerability in Older Adults With Cancer. , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] R. Kanesvaran,et al. Immunotherapy in Older Adults With Cancer. , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] P. Christopoulos,et al. Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer , 2021, International journal of molecular sciences.
[7] H. Cohen,et al. Predictors of Unplanned Hospitalizations Among Older Adults Receiving Cancer Chemotherapy , 2021, JCO oncology practice.
[8] E. Felip,et al. Pemetrexed Plus Platinum With or Without Pembrolizumab in Patients With Previously Untreated Metastatic Nonsquamous NSCLC: Protocol-Specified Final Analysis From KEYNOTE-189. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] P. Lorigan,et al. A prospective cohort study on the safety of checkpoint inhibitors in older cancer patients – the ELDERS study , 2021, ESMO open.
[10] S. Fröhling,et al. A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma , 2021, Oncoimmunology.
[11] A. Stenzinger,et al. Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA , 2020, EBioMedicine.
[12] C. Schumann,et al. Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP). , 2020, Lung cancer.
[13] H. Cohen,et al. Older adult participation in cancer clinical trials: A systematic review of barriers and interventions , 2020, CA: a cancer journal for clinicians.
[14] P. Christopoulos,et al. Breaking Bottlenecks for the TCR Therapy of Cancer , 2020, Cells.
[15] M. Kriegsmann,et al. Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing. , 2020, Lung cancer.
[16] A. Tafreshi,et al. A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer: Protocol-Specified Final Analysis of KEYNOTE-407. , 2020, Journal of Thoracic Oncology.
[17] A. Ardizzoni,et al. ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-A systematic review and meta-analysis of real world data. , 2020, Lung cancer.
[18] A. Stenzinger,et al. Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: Study protocol of the randomized phase II DURATION trial , 2020, Trials.
[19] S. Fröhling,et al. Quantifying potential confounders of panel-based tumor mutational burden (TMB) measurement. , 2020, Lung cancer.
[20] G. Galli,et al. Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer. , 2019, Lung cancer.
[21] Olaf Neumann,et al. Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases , 2019, International journal of cancer.
[22] A. Stenzinger,et al. Defining molecular risk in ALK+ NSCLC , 2019, Oncotarget.
[23] L. Heinzerling,et al. Senescence markers: Predictive for response to checkpoint inhibitors , 2018, International journal of cancer.
[24] A. Tafreshi,et al. Pembrolizumab plus Chemotherapy for Squamous Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.
[25] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[26] T. Mok,et al. Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study. , 2018, Journal of Clinical Oncology.
[27] Y. Shentu,et al. Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC). , 2018 .
[28] S. Novello,et al. Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.
[29] P. Brown,et al. Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA) , 2017, JAMA oncology.
[30] David Smith,et al. Frailty as determined by a comprehensive geriatric assessment‐derived deficit‐accumulation index in older patients with cancer who receive chemotherapy , 2016, Cancer.
[31] Y. Shentu,et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.
[32] Edward S. Kim,et al. Clinicopathologic Features of Advanced Squamous NSCLC. , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[33] G. Lyman,et al. Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High‐Age Patients (CRASH) score , 2012, Cancer.
[34] Supriya G Mohile,et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] Taofeek K Owonikoko,et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] M. Creditor. Hazards of Hospitalization of the Elderly , 1993, Annals of Internal Medicine.